Evidence map›Paper›PMID 39087871›Full record

Trial reportJournal of clinical pharmacology2024

Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.

Maiko Nomoto, Tomoko Hasunuma, Cuiyuan Cai, Ippei Suzuki, Ayano Mikubo, Setsuo Funasaka, Yohei Otake, Kenya Nakai, Sanae Yasuda

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maiko NomotoEisai Co., Ltd., Tokyo, Japan.
Tomoko HasunumaDepartment of Research, Clinical Trial Center, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.
Cuiyuan CaiEisai Co., Ltd., Tokyo, Japan.
Ippei SuzukiEisai Co., Ltd., Tokyo, Japan.
Ayano MikuboEisai Co., Ltd., Tokyo, Japan.
Setsuo FunasakaEisai Co., Ltd., Tokyo, Japan.
Yohei OtakeEisai Co., Ltd., Tokyo, Japan.
Kenya NakaiEisai Co., Ltd., Tokyo, Japan.
Sanae YasudaEisai Inc., Nutley, NJ, USA.

Funding

Eisai Co., LtdEisai Inc.
6 · The paper itself

Abstract

We conducted this three-part study in healthy subjects to investigate the pharmacokinetics of tasurgratinib (orally available selective inhibitor of fibroblast growth factor receptor 1-3) and M2 (its major metabolite) under different conditions. In Part A, subjects received tasurgratinib 35 mg either fed with a high-fat meal or fasted. In Parts B and C, subjects received tasurgratinib 35 mg alone or with either rabeprazole (acid-reducing agent) 20 mg (Part B) or rifampin (strong CYP3A inducer) 600 mg (Part C). Primary endpoints were maximum concentration (C

Indexed as

Cytochrome P-450 CYP3A InducersFood-Drug InteractionsRabeprazoleAdultArea Under CurveCross-Over StudiesCytochrome P-450 CYP3ADrug InteractionsFastingFemaleGastric AcidHumansMaleMiddle AgedPyrrolesReceptors, Fibroblast Growth Factor1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersPyrrolesRabeprazoleReceptors, Fibroblast Growth FactorRifampinSulfonamidesdrug‐drug interactionsFGFRfood effectpharmacokineticstasurgratinib

Identifiers

PMID39087871
PMCPMC11591400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.